Clinical value of <sup>99m</sup>Tc-PSMA SPECT/CT in detection of prostate cancer

HU Silong; XU Xiaoping; ZHU Yao; HE Simin; SU Hengchuan; YE Dingwei; GUO Xiaomao; ZHANG Yingjian

您当前的位置：

首页 >

文章列表页 >

Clinical value of ^99mTc-PSMA SPECT/CT in detection of prostate cancer

更新时间：2025-12-15

- Clinical value of ^99mTc-PSMA SPECT/CT in detection of prostate cancer
- Vol. 25, Issue 3, Pages: 272-278(2016)
- 作者机构：
  
  1. 复旦大学生物医学影像研究中心,上海,200032
  2. 上海分子影像探针工程技术研究中心筹,上海,200032
  3. 复旦大学上海医学院肿瘤学系,上海,200032
  4. 复旦大学附属肿瘤医院质子重离子中心,上海,201315
  5. 复旦大学附属肿瘤医院核医学科,上海,200032
  6. 复旦大学附属肿瘤医院泌尿外科,上海,200032
  7. 复旦大学附属肿瘤医院放疗科,上海,200032
- 作者简介：
- 基金信息：
- DOI：
  CLC：
- Published Online：02 November 2016，
  
  Published：02 November 2016
- 稿件说明：
移动端阅览
胡四龙,许晓平,朱耀,等. ^99mTc-PSMA SPECT/CT探测前列腺癌病灶的临床应用价值[J]. 肿瘤影像学, 2016, 25(3): 272-278
DOI：

胡四龙,许晓平,朱耀,等. ^99mTc-PSMA SPECT/CT探测前列腺癌病灶的临床应用价值[J]. 肿瘤影像学, 2016, 25(3): 272-278 DOI：

摘要

目的：

探讨

99m

Tc标记前列腺特异性膜抗原(prostate specific membrane antigen，PSMA)小分子抑制剂(HYNIC-Glu-Urea-A，简称99mTc-PSMA) SPECT/CT显像探测前列腺癌原发灶和转移灶的临床价值。

方法：

回顾性分析69例(初诊12例、经治57例)前列腺癌患者

99m

Tc-PSMA SPECT/CT结果，评价全身平面显像结合断层显像检测前列腺癌原发和(或)转移灶的价值，分析

99m

Tc-PSMA阳性率与前列腺特异性抗原(prostate specific antigen，PSA)水平和Gleason评分的关系。

结果：

所有69例患者中，6例根治术后PSA＜0.2 ng/mL患者为治愈状态，以患者为单位，

99m

Tc-PSMA阳性率77.8% (49/63)。

99m

Tc-PSMA阳性患者PSA水平 (中位数25.52 ng/mL，范围0.85~3 239 ng/mL)明显高于

99m

Tc-PSMA阴性患者PSA水平(中位数0.35 ng/mL，范围0.003~9.28 ng/mL)(

＜0.001)；在初诊和PSA＞1.0 ng/mL的复发患者中，阳性率高达97.4% (37/38)。

99m

Tc-PSMA阳性组患者Gleason评分高于阴性组患者(

＜0.001)。

结论：

对于前列腺癌初诊患者和PSA＞1.0 ng/mL的复发患者，

99m

Tc-PSMA SPECT/CT对原发灶和复发转移灶的探测有较高应用价值，可为临床提供重要的治疗决策依据。

Abstract

Objective:

To evaluate the clinical value of technetium-

99m

labelled small molecule against prostate specific membrane antigen (PSMA) (HYNIC-Glu-Urea-A

99m

Tc-PSMA) in the detection of primary and metastatic prostate cancers.

Methods:

A total of 69 consecutive prostate cancer patients wh

o received

99m

Tc-PSMA SPECT/CT were retrospectively analyzed. The sensitivity of

99m

Tc-PSMA for the detection of the primary and metastatic lesions was evaluated. The relationships between positive

99m

Tc-PSMA and prostate specific antigen (PSA) level and Gleason score were analyzed.

Results:

Of all patients

6 cases with PSA0.2 ng/mL after radical prostatectomy remained biochemically disease-free. Based on per patient

in 77.8% (49/63) of thepatients at least one lesion indicative of prostate cancer was detected by

99m

Tc-PSMA SPECT/CT. The level of PSA in the patients with positive

99m

Tc-PSMA imaging was significantly higher than that in the patients with negative

99m

Tc-PSMA imaging (PSA median 25.52 ng/mL

range: 0.85-3 239 ng/mL)

vs.

(PSA median 0.35 ng/mL

range: 0.003-9.28 ng/mL)(

0.001). Among newly diagnosed patients and recurrent patients with PSA1.0 ng/mL

99m

Tc-PSMA imaging was able to detect lesions with improved sensitivity of 97.4% (37/38); furthermore

among recurrent patients with PSA10.0 ng/mL

the number and extent of lesions detected by

99m

Tc- PSMA SPECT/CT increased significantly. Gleason score in the patients with positive

99m

Tc-PSMA imaging was significantly higher than that in the patients with negative

99m

Tc-PSMA imaging (

0.001).

Conclusion:

Among newly diagnosed prostate cancer patients and recurrent patients with PSA1.0 ng/mL

99m

Tc-PSMA SPECT/CT can detect prostate cancer and metastases in a high number of patients and can provide important information for clinical treatment decision.

关键词

Keywords

references

Views

2378

下载量

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Theranostics of targeted PSMA: application and progress

Initial clinical study of a novel prostate cancer imaging agent, ⁶⁸ Ga-PSMA-4PY

Comparison of correlations of reduced field-of-view and conventional apparent diffusion coefficients with Gleason score and percentage of tumor involvement in prostate core biopsy

Advances in radioimmunotherapy targeting prostate specific membrane antigen in prostate cancer

Evaluation of prostate cancer across different treatment stages using ¹⁸F-FDG PET imaging

Related Author

ZHANG Zhaoqi

ZHAO Xinming

ZHANG Xiaojun

LIU Huanhuan

LIU Yachao

WANG Ruimin

ZHANG Jinming

LIU Xiaohang

Related Institution

Clinical Medicine, Peking Union Medical College, Chinese Academy of Medical Sciences

Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Department of Nuclear Medicine, Affilitated Hospital of Southwest Medical University

Department of Nuclear Medicine, Chengdu Seventh People’s Hospital, Affilitated Cancer Hospital of Chengdu Medical College

Department of Radiology, Chengdu Seventh People’s Hospital, Affilitated Cancer Hospital of Chengdu Medical College

AI问答

⁰

Clinical value of 99mTc-PSMA SPECT/CT in detection of prostate cancer

DOI：

摘要

Abstract

关键词

Keywords

references

Clinical value of ^99mTc-PSMA SPECT/CT in detection of prostate cancer